Roche pledged ₩710 billion (about $485 million) and Eli Lilly committed $500 million to expand biopharma investment in South Korea over five years, signaling intensified industry focus on the country’s clinical‑trial infrastructure and manufacturing capacity. Both companies framed the investments as partnerships with local government to accelerate trials and development. The funds are aimed at building clinical trial hubs, supporting local biotech ecosystems and securing supply chains. Officials said the moves will enhance Korea’s standing as a regional life‑science center and could attract additional global R&D and manufacturing projects, creating new opportunities for local biotech collaborations and talent development.